FuRui Medical Technology (01696): The commercialization of Daxfield® (RT002) in China is progressing steadily

Zhitongcaijing · 07/28/2025 11:57

Zhitong Finance App News, FuRui Medical Technology (01696) issued an announcement. The company is aware that the market continues to pay attention to the commercialization progress of its re-authorized product RT002 (trademark Daxifei® in China, DAXXIFY® in English, generic name DaxiBotulinumToxina-LANM) in mainland China.

The company only stated that as of the date of this announcement, the commercialization of this product in mainland China was progressing steadily. Related business preparations such as regulatory declarations, market entry, and professional team building are carried out in an orderly manner. The company is confident of the product's application prospects in the Chinese market and will disclose further information in due course based on actual progress.